Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
RCAvita Medical Inc. logo

Avita Medical Inc. (RCEL)

NASDAQ · Currency in USD
$15.16 ▼ -0.35 (-2.26%)
As of Oct 26, 12:29 PM ET. Market open.

Summary

Previous Close
$15.51
Open
$15.50
Day's Range
$14.83 – $15.54
52 Week Range
$3.22 – $15.68
Volume
149,338
Avg. Volume
438,162
Market Cap
$376.62M
Beta (5Y Monthly)
1.99
PE Ratio (TTM)
--
EPS (TTM)
-$1.40
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.50

Profile: Avita Medical Inc.

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
226
CEO
Cary G. Vance

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.24 · Revenue est. $22.35M
DateEst.Actual
Aug 6, 2026-$0.29-$0.25Beat
May 14, 2026-$0.35-$0.35Beat
Feb 12, 2026-$0.36-$0.38Miss
Nov 6, 2025-$0.43-$0.46Miss
Aug 7, 2025-$0.26-$0.38Miss
May 8, 2025-$0.39-$0.53Miss

Analyst view

Consensus price target
$11.50 ▼ -24.1%
Range $11.00 – $12.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on RCEL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.